<p>Jump Financial LLC 在第二季度购买了 West Pharmaceutical Services, Inc. (NYSE:WST - 免费报告) 的新头寸，根据该公司最近向美国证券交易委员会提交的 13F 表格。该公司购买了 20,239 股这家医疗器械供应商的股票，价值约为 4,428,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他一些对冲基金和机构投资者也增加或减少了对该股票的持股。SYM FINANCIAL Corp 在第二季度将其在 West Pharmaceutical Services 的持股增加了 5.1%。SYM FINANCIAL Corp 目前拥有 1,027 股这家医疗器械供应商的股票，价值 225,000 美元，在此期间又购买了 50 股。Parkside Financial Bank &amp; Trust 在第二季度将其在 West Pharmaceutical Services 的持股增加了 4.0%。Parkside Financial Bank &amp; Trust 目前拥有 1,318 股这家医疗器械供应商的股票，价值 288,000 美元，在上个季度又收购了 51 股。MJP Associates Inc. ADV 在第二季度将其在 West Pharmaceutical Services 的持股增加了 2.7%。MJP Associates Inc. ADV 目前拥有 1,970 股这家医疗器械供应商的股票，价值 431,000 美元，在上个季度又收购了 52 股。Horizon Investments LLC 在第一季度将其在 West Pharmaceutical Services 的持股增加了 5.8%。Horizon Investments LLC 目前拥有 1,048 股这家医疗器械供应商的股票，价值 234,000 美元，在此期间又收购了 57 股。最后，Pallas Capital Advisors LLC 在第二季度将其在 West Pharmaceutical Services 的持股增加了 1.0%。Pallas Capital Advisors LLC 目前拥有 6,333 股这家医疗器械供应商的股票，价值 1,386,000 美元，在上个季度又购买了 62 股。机构投资者和对冲基金持有该公司 93.90% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>几家研究公司对 WST 发表了评论。德意志银行设定了 West Pharmaceutical Services 股票的目标价为 345.00 美元，并在 10 月 24 日的研究报告中给予该股票 &#34;买入&#34; 评级。Wall Street Zen 在周六的报告中将 West Pharmaceutical Services 的评级从 &#34;买入&#34; 下调至 &#34;持有&#34;。Rothschild &amp; Co Redburn 在 9 月 15 日的研究报告中开始覆盖 West Pharmaceutical Services。他们对该股票给予了 &#34;买入&#34; 评级，并设定了 311.00 美元的目标价。瑞银集团在 10 月 24 日的研究报告中将 West Pharmaceutical Services 的目标价从 320.00 美元上调至 355.00 美元，并给予该股票 &#34;买入&#34; 评级。最后，Cowen 在 10 月 29 日的研究报告中开始覆盖 West Pharmaceutical Services。他们对该公司给予了 &#34;买入&#34; 评级。两位股票研究分析师对该股票给予了强烈买入评级，九位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 343.36 美元。</p>
<ul>
<li>今年将推动标准普尔 500 指数表现的因素是什么？</li>
</ul>
<p><strong>查看我们最新的 West Pharmaceutical Services 股票报告</strong></p>
<h2>West Pharmaceutical Services 股票表现</h2>
<p>WST 周三开盘价为 266.02 美元。该公司的市值为 191.4 亿美元，市盈率为 39.41，市盈增长比率为 4.16，贝塔值为 1.17。该公司的债务与股本比率为 0.07，流动比率为 2.87，速动比率为 2.18。West Pharmaceutical Services, Inc. 的一年低点为 187.43 美元，一年高点为 348.90 美元。该公司的 50 日移动平均价格为 273.94 美元，200 日移动平均价格为 249.16 美元。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>West Pharmaceutical Services (NYSE:WST - 获取免费报告) 最近在 10 月 23 日发布了季度财报。这家医疗器械供应商报告每股收益 (EPS) 为 1.96 美元，超出市场共识预期的 1.67 美元，超出 0.29 美元。该公司季度收入为 8.046 亿美元，而分析师预期为 7.8842 亿美元。West Pharmaceutical Services 的股本回报率为 18.16%，净利润率为 16.29%。该公司的季度收入同比增长 7.7%。去年同期，该公司每股收益为 1.85 美元。West Pharmaceutical Services 已将其 2025 财年的指引设定为每股收益 7.060-7.110。研究分析师预测 West Pharmaceutical Services, Inc. 本财年将发布 6.62 美元的每股收益。</p>
<h2>West Pharmaceutical Services 公司简介</h2>
<p>(免费报告)</p>
<p>West Pharmaceutical Services, Inc. 设计、制造并销售用于注射药物和医疗保健产品的封闭和输送系统，业务遍及美洲、欧洲、中东、非洲和亚太地区。它分为两个部门，专有产品和合同制造产品。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 West Pharmaceutical Services</li>
<li>什么是稀释每股收益 (Diluted EPS)？</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年爆发</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>安海斯 - 布希收购 BeatBox 以赢得年轻饮酒者</li>
</ul>
<p><strong>想看看其他对冲基金持有的 WST 吗？</strong> 访问 HoldingsChannel.com 获取 West Pharmaceutical Services, Inc. (NYSE:WST - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

<p>Jump Financial LLC 在第二季度投资了 443 万美元于西氏医药服务公司，购买了 20,239 股。其他机构投资者也调整了他们的持仓。分析师的评级意见不一，普遍共识为 “适度买入”，目标价格为 343.36 美元。西氏医药服务公司报告第三季度每股收益为 1.96 美元，超出预期，营收同比增长 7.7%。该公司的市值为 191.4 亿美元，1 年股票价格区间为 187.43 美元至 348.90 美元</p>

<p>Jump Financial LLC purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 20,239 shares of the medical instruments supplier's stock, valued at approximately $4,428,000.</p>
<div class="lb-trans"><p>Jump Financial LLC 在第二季度购买了 West Pharmaceutical Services, Inc. (NYSE:WST - 免费报告) 的新头寸，根据该公司最近向美国证券交易委员会提交的 13F 表格。该公司购买了 20,239 股这家医疗器械供应商的股票，价值约为 4,428,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. SYM FINANCIAL Corp increased its position in West Pharmaceutical Services by 5.1% in the second quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 50 shares during the period. Parkside Financial Bank &amp; Trust grew its position in shares of West Pharmaceutical Services by 4.0% during the second quarter. Parkside Financial Bank &amp; Trust now owns 1,318 shares of the medical instruments supplier's stock worth $288,000 after acquiring an additional 51 shares during the last quarter. MJP Associates Inc. ADV grew its position in shares of West Pharmaceutical Services by 2.7% during the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier's stock worth $431,000 after acquiring an additional 52 shares during the last quarter. Horizon Investments LLC increased its holdings in shares of West Pharmaceutical Services by 5.8% in the 1st quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier's stock worth $234,000 after acquiring an additional 57 shares during the period. Finally, Pallas Capital Advisors LLC lifted its position in West Pharmaceutical Services by 1.0% in the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier's stock valued at $1,386,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也增加或减少了对该股票的持股。SYM FINANCIAL Corp 在第二季度将其在 West Pharmaceutical Services 的持股增加了 5.1%。SYM FINANCIAL Corp 目前拥有 1,027 股这家医疗器械供应商的股票，价值 225,000 美元，在此期间又购买了 50 股。Parkside Financial Bank &amp; Trust 在第二季度将其在 West Pharmaceutical Services 的持股增加了 4.0%。Parkside Financial Bank &amp; Trust 目前拥有 1,318 股这家医疗器械供应商的股票，价值 288,000 美元，在上个季度又收购了 51 股。MJP Associates Inc. ADV 在第二季度将其在 West Pharmaceutical Services 的持股增加了 2.7%。MJP Associates Inc. ADV 目前拥有 1,970 股这家医疗器械供应商的股票，价值 431,000 美元，在上个季度又收购了 52 股。Horizon Investments LLC 在第一季度将其在 West Pharmaceutical Services 的持股增加了 5.8%。Horizon Investments LLC 目前拥有 1,048 股这家医疗器械供应商的股票，价值 234,000 美元，在此期间又收购了 57 股。最后，Pallas Capital Advisors LLC 在第二季度将其在 West Pharmaceutical Services 的持股增加了 1.0%。Pallas Capital Advisors LLC 目前拥有 6,333 股这家医疗器械供应商的股票，价值 1,386,000 美元，在上个季度又购买了 62 股。机构投资者和对冲基金持有该公司 93.90% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research firms have commented on WST. Deutsche Bank Aktiengesellschaft set a $345.00 target price on shares of West Pharmaceutical Services and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 24th. Wall Street Zen lowered West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Rothschild &amp; Co Redburn assumed coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They issued a &#34;buy&#34; rating and a $311.00 target price on the stock. UBS Group boosted their price target on West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 24th. Finally, Cowen started coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a &#34;buy&#34; rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $343.36.</p>
<div class="lb-trans"><p>几家研究公司对 WST 发表了评论。德意志银行设定了 West Pharmaceutical Services 股票的目标价为 345.00 美元，并在 10 月 24 日的研究报告中给予该股票 &#34;买入&#34; 评级。Wall Street Zen 在周六的报告中将 West Pharmaceutical Services 的评级从 &#34;买入&#34; 下调至 &#34;持有&#34;。Rothschild &amp; Co Redburn 在 9 月 15 日的研究报告中开始覆盖 West Pharmaceutical Services。他们对该股票给予了 &#34;买入&#34; 评级，并设定了 311.00 美元的目标价。瑞银集团在 10 月 24 日的研究报告中将 West Pharmaceutical Services 的目标价从 320.00 美元上调至 355.00 美元，并给予该股票 &#34;买入&#34; 评级。最后，Cowen 在 10 月 29 日的研究报告中开始覆盖 West Pharmaceutical Services。他们对该公司给予了 &#34;买入&#34; 评级。两位股票研究分析师对该股票给予了强烈买入评级，九位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 343.36 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年将推动标准普尔 500 指数表现的因素是什么？</li>
</ul>
</div><p><strong>View Our Latest Stock Report on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 West Pharmaceutical Services 股票报告</strong></p>
</div><h2>West Pharmaceutical Services Stock Performance</h2>
<div class="lb-trans"><h2>West Pharmaceutical Services 股票表现</h2>
</div><p>WST opened at $266.02 on Wednesday. The company has a market capitalization of $19.14 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 4.16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $348.90. The business has a 50 day moving average price of $273.94 and a two-hundred day moving average price of $249.16.</p>
<div class="lb-trans"><p>WST 周三开盘价为 266.02 美元。该公司的市值为 191.4 亿美元，市盈率为 39.41，市盈增长比率为 4.16，贝塔值为 1.17。该公司的债务与股本比率为 0.07，流动比率为 2.87，速动比率为 2.18。West Pharmaceutical Services, Inc. 的一年低点为 187.43 美元，一年高点为 348.90 美元。该公司的 50 日移动平均价格为 273.94 美元，200 日移动平均价格为 249.16 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million for the quarter, compared to analysts' expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>West Pharmaceutical Services (NYSE:WST - 获取免费报告) 最近在 10 月 23 日发布了季度财报。这家医疗器械供应商报告每股收益 (EPS) 为 1.96 美元，超出市场共识预期的 1.67 美元，超出 0.29 美元。该公司季度收入为 8.046 亿美元，而分析师预期为 7.8842 亿美元。West Pharmaceutical Services 的股本回报率为 18.16%，净利润率为 16.29%。该公司的季度收入同比增长 7.7%。去年同期，该公司每股收益为 1.85 美元。West Pharmaceutical Services 已将其 2025 财年的指引设定为每股收益 7.060-7.110。研究分析师预测 West Pharmaceutical Services, Inc. 本财年将发布 6.62 美元的每股收益。</p>
</div><h2>West Pharmaceutical Services Profile</h2>
<div class="lb-trans"><h2>West Pharmaceutical Services 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>West Pharmaceutical Services, Inc. 设计、制造并销售用于注射药物和医疗保健产品的封闭和输送系统，业务遍及美洲、欧洲、中东、非洲和亚太地区。它分为两个部门，专有产品和合同制造产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 West Pharmaceutical Services</li>
<li>什么是稀释每股收益 (Diluted EPS)？</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年爆发</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>安海斯 - 布希收购 BeatBox 以赢得年轻饮酒者</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 WST 吗？</strong> 访问 HoldingsChannel.com 获取 West Pharmaceutical Services, Inc. (NYSE:WST - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Jump Financial LLC 投资 443 万美元于西氏医药服务公司（West Pharmaceutical Services, Inc.）$WST